XFXavier Fradera

Xavier Fradera

*This is an algorithmically generated author record based on publicly available information.

Xavier Fradera has a total of 420 co-authors. Here are the top co-authors by number of shared publications:

  • Miquel Duran

    Institut de Química Computacional and Departament de Química, Universitat de Girona, 17071 Girona, Catalonia, Spain

    16 shared publications
  • Hua Zhou

    Departments of Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    11 shared publications
  • J. Richard Miller

    Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    10 shared publications
  • Miquel Solà

    Institut de Química Computacional i Catàlisi and Departament de Química, Universitat de Girona, c/ Maria Aurèlia Capmany 69, 17003 Girona, Catalonia, Spain

    10 shared publications
  • Abdelghani Achab

    Departments of Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    9 shared publications
  • Meredeth A. McGowan

    Departments of Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

    9 shared publications

Latest Publications

  • Discovery of Potent and Selective Benzothiophene Difluoromethyl Phosphonate (DFMP) PTPN2/N1-Dual Inhibitors

    by Xiao Mei Zheng, David A. Candito, James Jewell, Matthew Childers, Shuhei Kawamura, Kaitlyn M. Logan, Ryan D. Otte, Charles S. Yeung, Dong Xiao, Ping Liu, et al.

    PTPN1 and PTPN2 are interesting targets for immuno-oncology due to their ability to modulate IFNγ signaling and T-cell activity. We report the discovery of benzothiophene difluoromethyl phosphonate (DFMP) inhibitors with potent dual PTPN1/PTPN2 activity. Structure-based design and a late-stage Ir-catalyzed C–H borylation enabled C5/C7-disubstituted designs that produced a marked inflection in potency. Systematic vector optimization improved potency, selectivity, and pharmacokinetic properties. Mechanistic studies identified SLC19A1 as a key transporter mediating cellular uptake. Lead compound 25 exhibited good potency, high selectivity, favorable PK, and dose-dependent pSTAT1 induction in a MC38 mouse model. These results establish compound 25 as promising structurally differentiated tool to study PTPN1/N2 inhibition and underscore the importance of SLC19A1 in the transport of DFMPs.


  • Diminishing GSH-Adduct Formation of Tricyclic Diazepine-based Mutant IDH1 Inhibitors

    by Chunhui Huang, Christian Fischer, Michelle R. Machacek, Stephane Bogen, Tesfaye Biftu, Xianhai Huang, Michael H. Reutershan, Ryan Otte, Qingmei Hong, Zhicai Wu, et al.

    Mutant isocitrate dehydrogenase 1 (IDH1) has been identified as an attractive oncology target for which >70% of grade II and III gliomas and ∼10% of acute myeloid leukemia (AML) harbor somatic IDH1 mutations. These mutations confer a neomorphic gain of function, leading to the production of the oncometabolite (R)-2-hydroxyglutarate (2-HG). We identified and developed a potent, selective, and orally bioavailable brain-penetrant tricyclic diazepine scaffold that inhibits mutant IDH1. During the course of in vitro metabolism studies, GSH-adduct metabolites were observed. The hypothesis for GSH-adduct formation was driven by the electron-rich nature of the tricyclic core. Herein, we describe our efforts to reduce the electron-rich nature of the core. Ultimately, a strategy focused on core modifications to block metabolic hot spots coupled with substitution pattern changes (C8 N → C linked) led to the identification of new tricyclic analogues with minimal GSH-adduct formation across species while maintaining an overall balanced profile.


  • Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing

    by Derun Li, David L. Sloman, Abdelghani Achab, Hua Zhou, Meredeth A. McGowan, Catherine White, Craig Gibeau, Hongjun Zhang, Qinglin Pu, Indu Bharathan, et al.

    3,3-Disubstituted oxetanes have been utilized as bioisosteres for gem-dimethyl and cyclobutane functionalities. We report the discovery of a novel class of oxetane indole-amine 2,3-dioxygenase (IDO1) inhibitors suitable for Q3W (once every 3 weeks) oral and parenteral dosing. A diamide class of IDO inhibitors was discovered through an automated ligand identification system (ALIS). Installation of an oxetane and fluorophenyl dramatically improved the potency. Identification of a biaryl moiety as an unconventional amide isostere addressed the metabolic liability of amide hydrolysis. Metabolism identification (Met-ID)-guided target design and the introduction of polarity resulted in the discovery of potent IDO inhibitors with excellent pharmacokinetic (PK) profiles in multiple species. To enable rapid synthesis of the key oxetane intermediate, a novel oxetane ring cyclization was also developed, as well as optimization of a literature route on kg scale. These IDO inhibitors may enable unambiguous proof-of-concept testing for the IDO1 inhibition mechanism for oncology.


  • Open Access

    NMR Data‐Driven Docking of HDM2‐Inhibitor Complexes

    by Xavier Fradera, Michael H. Reutershan, Michelle R. Machacek, B. Wesley Trotter, Mark A. McCoy

    We present an automated NMR‐guided docking workflow that can be used to generate models of protein‐ligand complexes based on data from NOE NMR experiments. The first step is to generate a number of intermolecular distance constraints from experimental NOE data. Then, the ligand is docked on an ensemble of receptor structures to account for protein flexibility, and multiple poses are generated. Finally, we use the NOE‐based constraints to filter and score docking poses based on the percentage of NOE constraints that are consistent with protein‐ligand interatomic distances. This workflow was successfully used during a lead optimization project to generate models of synthetic protein‐protein interaction (PPI) inhibitors bound to the HDM2 protein.


  • Discovery of MK-4688: an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction

    by Michael H. Reutershan, Michelle R. Machacek, Michael D. Altman, Stephane Bogen, Mingmei Cai, Carolyn Cammarano, Dapeng Chen, Matthew Christopher, John Cryan, Pierre Daublain, et al.

    Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein–protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward this goal. Adding to recent success in this area, we describe herein our efforts to optimize a novel purine carboxylic acid-derived inhibitor of the HDM2–p53 PPI into a series of low-projected dose inhibitors with overall favorable pharmacokinetic and physical properties. Ultimately, a strategy focused on leveraging known binding hot spots coupled with biostructural information to guide the design of conformationally constrained analogs and a focus on efficiency metrics led to the discovery of MK-4688 (compound 56), a highly potent, selective, and low-molecular-weight inhibitor suitable for clinical investigation.


  • Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors

    by Brett Hopkins, Hongjun Zhang, Indu Bharathan, Derun Li, Qinglin Pu, Hua Zhou, Theodore A. Martinot, Xavier Fradera, Alfred Lammens, Charles A. Lesburg, et al.


  • Open Access

    Structural insights on ligand recognition at the human leukotriene B4 receptor 1

    by Nairie Michaelian, Anastasiia Sadybekov, Élie Besserer-Offroy, Gye Won Han, Harini Krishnamurthy, Beata A. Zamlynny, Xavier Fradera, Phieng Siliphaivanh, Jeremy Presland, Kerrie B. Spencer, et al.

    The leukotriene B4 receptor 1 (BLT1) regulates the recruitment and chemotaxis of different cell types and plays a role in the pathophysiology of infectious, allergic, metabolic, and tumorigenic human diseases. Here we present a crystal structure of human BLT1 (hBLT1) in complex with a selective antagonist MK-D-046, developed for the treatment of type 2 diabetes and other inflammatory conditions. Comprehensive analysis of the structure and structure-activity relationship data, reinforced by site-directed mutagenesis and docking studies, reveals molecular determinants of ligand binding and selectivity toward different BLT receptor subtypes and across species. The structure helps to identify a putative membrane-buried ligand access channel as well as potential receptor binding modes of endogenous agonists. These structural insights of hBLT1 enrich our understanding of its ligand recognition and open up future avenues in structure-based drug design.


  • Discovery of a new series of PI3K-δ inhibitors from Virtual Screening

    by Xavier Fradera, Qiaolin Deng, Abdelganhi Achab, Yudith Garcia, Solomon D. Kattar, Meredeth A. McGowan, Joey L. Methot, Kevin Wilson, Hua Zhou, Lynsey Shaffer, et al.


  • Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators

    by Joey L. Methot, Hua Zhou, Meredeth A. McGowan, Neville John Anthony, Matthew Christopher, Yudith Garcia, Abdelghani Achab, Kathryn Lipford, Benjamin Wesley Trotter, Michael D. Altman, et al.

    The approvals of idelalisib and duvelisib have validated PI3Kδ inhibitors for the treatment for hematological malignancies driven by the PI3K/AKT pathway. Our program led to the identification of structurally distinct heterocycloalkyl purine inhibitors with excellent isoform and kinome selectivity; however, they had high projected human doses. Improved ligand contacts gave potency enhancements, while replacement of metabolic liabilities led to extended half-lives in preclinical species, affording PI3Kδ inhibitors with low once-daily predicted human doses. Treatment of C57BL/6-Foxp3-GDL reporter mice with 30 and 100 mg/kg/day of 3c (MSD-496486311) led to a 70% reduction in Foxp3-expressing regulatory T cells as observed through bioluminescence imaging with luciferin, consistent with the role of PI3K/AKT signaling in Treg cell proliferation. As a model for allergic rhinitis and asthma, treatment of ovalbumin-challenged Brown Norway rats with 0.3 to 30 mg/kg/day of 3c gave a dose-dependent reduction in pulmonary bronchoalveolar lavage inflammation eosinophil cell count.


  • Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

    by Brandon A. Vara, Samuel M. Levi, Abdelghani Achab, David A. Candito, Xavier Fradera, Charles A. Lesburg, Shuhei Kawamura, Brian M. Lacey, Jongwon Lim, Joey L. Methot, et al.

    Hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase, is a negative immune regulator of T cell receptor (TCR) and B cell signaling that is primarily expressed in hematopoietic cells. Accordingly, it has been reported that HPK1 loss-of-function in HPK1 kinase-dead syngeneic mouse models shows enhanced T cell signaling and cytokine production as well as tumor growth inhibition in vivo, supporting its value as an immunotherapeutic target. Herein, we present the structurally enabled discovery of novel, potent, and selective diaminopyrimidine carboxamide HPK1 inhibitors. The key discovery of a carboxamide moiety was essential for enhanced enzyme inhibitory potency and kinome selectivity as well as sustained elevation of cellular IL-2 production across a titration range in human peripheral blood mononuclear cells. The elucidation of structure–activity relationships using various pendant amino ring systems allowed for the identification of several small molecule type-I inhibitors with promising in vitro profiles.